Scarica l'app Stockscreener
0.425
2.43%
-0.0106
Dopo l'orario di chiusura:
.41
-0.015
-3.53%
Precedente Chiudi:
$0.4356
Aprire:
$0.41
Volume 24 ore:
142.54K
Relative Volume:
0.09
Capitalizzazione di mercato:
$6.72M
Reddito:
$1.84M
Utile/perdita netta:
$-17.51M
Rapporto P/E:
-0.3069
EPS:
-1.3849
Flusso di cassa netto:
$-17.30M
1 W Prestazione:
+2.24%
1M Prestazione:
-21.21%
6M Prestazione:
-45.78%
1 anno Prestazione:
-62.05%
Intervallo 1D:
$0.4067
$0.451
Intervallo di 1 settimana:
$0.3521
$0.47
Portata 52W:
$0.3521
$1.50
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.425 | 6.57M | 1.84M | -17.51M | -17.30M | -1.3849 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-08 | Iniziato | ROTH Capital | Buy |
| 2021-07-29 | Iniziato | Aegis Capital | Buy |
| 2020-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2013-12-16 | Iniziato | Oppenheimer | Outperform |
Evogene Ltd Borsa (EVGN) Ultime notizie
Evogene Director Nir Nimrodi Awarded 10,000 Stock Options Under 2021 Incentive Plan - kalkinemedia.com
Form 4 Evogene Ltd. For: 30 September By Investing.com - Investing.com Nigeria
Evogene Ltd. SEC Filing (Sep 30, 2026) - Stock Titan
Director receives 2,500 options with a $0.58 exercise price from Evogene (EVGN). - Stock Titan
10,000 options with a $0.58 exercise price go to Evogene (EVGN) director Nir Nimrodi. - Stock Titan
A director receives 2,500 Evogene (EVGN) stock options with a $0.58 exercise price. - Stock Titan
Evogene receives 180-day extension for Nasdaq compliance - Investing.com
Evogene gets Nasdaq extension to regain $1 mini... - Pluang
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance - PR Newswire
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
After about $2M in seed sales a year earlier, first-half revenue fell at Evogene (EVGN). - Stock Titan
All 3,384,616 shares were sold; Evogene (EVGN) moves to end their resale registration. - Stock Titan
Evogene Stock Price Forecast. Should You Buy EVGN? - StockInvest.us
EVGN Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 6.48% Share GainEarnings Manipulation Risk - dars.gov.et
Evogene stock falls to USD 0.50 after board turmoil - AD HOC NEWS
Evogene Faces Dissident Shareholder Tender Offer and Board Resignations After September AGM - TipRanks
Two Evogene (EVGN) directors resign amid investor claims over AGM vote - Stock Titan
L.I.A. Pure Capital Intends to Commence a Special Tender Offer to Evogene - marketscreener.com
Evogene (NASDAQ: EVGN) Share Price, EVGN Stock News, EVGN Share Price & Updates - Kalkine
Investor group in Evogene (NASDAQ: EVGN) plans a special tender offer under Israeli law - Stock Titan
8.6% Evogene (EVGN) holder bought 1.26M shares in August - Stock Titan
Casterra announces $2.2 Mn of purchase orders to supply castor seeds - AgroSpectrum India
Evogene Confirms Board Slate at September 4 Shareholder Meeting - TipRanks
Evogene Ltd. Approves Board Appointments - marketscreener.com
Evogene (EVGN) sets seven-member board after 2026 shareholder vote - Stock Titan
Evogene stock trades lower as biotech investors eye latest pipeline moves - AD HOC NEWS
L.I.A. Pure Capital Acquires 19.35% Activist Stake in Evogene (NASDAQ: EVGN) - Kalkine Media
L.I.A. Pure Capital Takes 19.35% Activist Stake in Evogene (NASDAQ: EVGN), Pushes for Board Changes - kalkinemedia.com
Evogene Ltd. (EVGN) stock price, news, quote and history - Yahoo Finance Australia
Evogene urges shareholders to support current b... - pluang.com
Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward - TradingView
Evogene stock holds steady as investors eye latest genomics progress - ad-hoc-news.de
Evogene (EVGN) investor group pushes for board seats at annual meeting - Stock Titan
[6-K] Evogene Ltd. Current Report (Foreign Issuer) - Stock Titan
Evogene | 4: Statement of changes in beneficial ownership of securities-Officer Tarcic Gabi - Moomoo
ISS and Glass Lewis back Evogene board nominees ahead of vote - Investing.com India
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees - PR Newswire
Evogene Ltd (EVGN) Stock News Today - tradingkey.com
Evogene (EVGN) Momentum: Ends Higher by 3.14% at $0.60 on the Day; Next Session: $0.57 and $0.63 Define the Nearby Reference Levels for the Current SessionMoney Flow - dars.gov.et
Evogene Ltd. Q2 2026 Earnings Call Summary - Yahoo Finance
Evogene | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
Evogene earnings beat by $0.15, revenue topped estimates - Investing.com India
Evogene Q2 2026 Deep Dive: EPS Beats, Revenue Down 35% - AlphaStreet
Teleconferência de Resultados do 2T26 da Evogene (EVGN): Prejuízo Diminui com Expansão da ChemPass AI - TradingKey
Evogene Q2 2026: Loss Narrows 50.0% to -$0.14/Share, Revenue Down 35% - AlphaStreet
Earnings call transcript: Evogene narrows Q2 2026 loss as shares fall 7.8% - Investing.com Nigeria
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation - Global Agriculture
EVGN: Q2 net loss down 62% year-over-year as AI-driven focus delivers operational and financial gains - TradingView
EVGN: Q2 2026 net loss fell 62% year-over-year as AI-driven transformation boosted efficiency - TradingView
Evogene: Q2 Earnings Snapshot - theheraldreview.com
Evogene Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Evogene Ltd Azioni (EVGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Evogene Ltd Azioni (EVGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| RECANATI LEON | Director |
Aug 11 '26 |
Buy |
0.64 |
460,000 |
292,100 |
1,343,886 |
| RECANATI LEON | Director |
Aug 04 '26 |
Buy |
0.50 |
800,000 |
400,000 |
883,886 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):